Skip to main content
SpringerLink
Log in

FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Fibroblast growth factor 13 (FGF13) is aberrantly expressed in multiple cancer types, suggesting its essential role in tumorigenesis. Hence, we aimed to explore its definite role in the development of acute myeloid leukemia (AML) and emphasize its associations with bone marrow niches. Results showed that FGF13 was lowly expressed in patients with AML and that its elevated expression was related to prolonged overall survival (OS). Univariate and multivariate Cox regression analyses identified FGF13 as an independent prognostic factor. A prognostic nomogram integrating FGF13 and clinicopathologic variables was constructed to predict 1-, 3-, and 5-year OS. Gene mutation and functional analyses indicated that FGF13 was not associated with AML driver mutations but was related to bone marrow niches. As for immunity, FGF13 was remarkably associated with T cell count, immune checkpoint genes, and cytokines. In addition, FGF13 overexpression substantially inhibited the growth and significantly induced the early apoptosis of AML cells. The xenograft study indicated that FGF13 overexpression prolonged the survival of recipient mice. Overall, FGF13 could serve as an independent prognostic factor for AML, and it was closely related to the bone marrow microenvironment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol 2021; 18(9): 577–590

    Article  Google Scholar 

  2. Assi SA, Imperato MR, Coleman DJL, Pickin A, Potluri S, Ptasinska A, Chin PS, Blair H, Cauchy P, James SR, Zacarias-Cabeza J, Gilding LN, Beggs A, Clokie S, Loke JC, Jenkin P, Uddin A, Delwel R, Richards SJ, Raghavan M, Griffiths MJ, Heidenreich O, Cockerill PN, Bonifer C. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nat Genet 2019; 51(1): 151–162

    Article  CAS  Google Scholar 

  3. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129(4): 424–447

    Article  Google Scholar 

  4. Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS. Bone marrow niches in haematological malignancies. Nat Rev Cancer 2020; 20(5): 285–298

    Article  Google Scholar 

  5. Mancini SJC, Balabanian K, Corre I, Gavard J, Lazennec G, Le Bousse-Kerdilès MC, Louache F, Maguer-Satta V, Mazure NM, Mechta-Grigoriou F, Peyron JF, Trichet V, Herault O. Deciphering tumor niches: lessons from solid and hematological malignancies. Front Immunol 2021; 12: 766275

    Article  CAS  Google Scholar 

  6. Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 2016; 15(1): 51–69

    Article  CAS  Google Scholar 

  7. Olsen SK, Garbi M, Zampieri N, Eliseenkova AV, Ornitz DM, Goldfarb M, Mohammadi M. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem 2003; 278(36): 34226–34236

    Article  CAS  Google Scholar 

  8. Wei EQ, Sinden DS, Mao L, Zhang H, Wang C, Pitt GS. Inducible Fgf13 ablation enhances caveolae-mediated cardioprotection during cardiac pressure overload. Proc Natl Acad Sci USA 2017; 114(20): E4010–E4019

    Article  CAS  Google Scholar 

  9. Wu QF, Yang L, Li S, Wang Q, Yuan XB, Gao X, Bao L, Zhang X. Fibroblast growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migration. Cell 2012; 149(7): 1549–1564

    Article  CAS  Google Scholar 

  10. Lu H, Shi X, Wu G, Zhu J, Song C, Zhang Q, Yang G. FGF13 regulates proliferation and differentiation of skeletal muscle by down-regulating Spry1. Cell Prolif 2015; 48(5): 550–560

    Article  CAS  Google Scholar 

  11. Okada T, Murata K, Hirose R, Matsuda C, Komatsu T, Ikekita M, Nakawatari M, Nakayama F, Wakatsuki M, Ohno T, Kato S, Imai T, Imamura T. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells. Sci Rep 2013; 3(1): 2899

    Article  Google Scholar 

  12. Lu H, Yin M, Wang L, Cheng J, Cheng W, An H, Zhang T. FGF13 interaction with SHCBP1 activates AKT-GSK3α/β signaling and promotes the proliferation of A549 cells. Cancer Biol Ther 2020; 21(11): 1014–1024

    Article  CAS  Google Scholar 

  13. Johnstone CN, Pattison AD, Harrison PF, Powell DR, Lock P, Ernst M, Anderson RL, Beilharz TH. FGF13 promotes metastasis of triple-negative breast cancer. Int J Cancer 2020; 147(1): 230–243

    Article  CAS  Google Scholar 

  14. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39(4): 782–795

    Article  CAS  Google Scholar 

  15. Li R, Zhang L, Qin Z, Wei Y, Deng Z, Zhu C, Tang J, Ma L. High LINC00536 expression promotes tumor progression and poor prognosis in bladder cancer. Exp Cell Res 2019; 378(1): 32–40

    Article  CAS  Google Scholar 

  16. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15(1): 49–63

    Article  CAS  Google Scholar 

  17. Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood 2018; 132(10): 1007–1012

    Article  CAS  Google Scholar 

  18. Otani Y, Ichikawa T, Kurozumi K, Inoue S, Ishida J, Oka T, Shimizu T, Tomita Y, Hattori Y, Uneda A, Matsumoto Y, Michiue H, Date I. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. Oncogene 2018; 37(6): 777–786

    Article  CAS  Google Scholar 

  19. Turkowski K, Herzberg F, Günther S, Brunn D, Weigert A, Meister M, Muley T, Kriegsmann M, Schneider MA, Winter H, Thomas M, Grimminger F, Seeger W, Savai Pullamsetti S, Savai R. Fibroblast growth factor-14 acts as tumor suppressor in lung adenocarcinomas. Cells 2020; 9(8): E1755

    Article  Google Scholar 

  20. Su T, Huang L, Zhang N, Peng S, Li X, Wei G, Zhai E, Zeng Z, Xu L. FGF14 functions as a tumor suppressor through inhibiting PI3K/AKT/mTOR pathway in colorectal cancer. J Cancer 2020; 11(4): 819–825

    Article  CAS  Google Scholar 

  21. Wu X, Li M, Li Y, Deng Y, Ke S, Li F, Wang Y, Zhou S. Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway. J Transl Med 2021; 19(1): 353

    Article  CAS  Google Scholar 

  22. Li J, Cao J, Li P, Yao Z, Deng R, Ying L, Tian J. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis. BMC Cancer 2021; 21(1): 858

    Article  CAS  Google Scholar 

  23. Li K, Tay FR, Yiu CKY. The past, present and future perspectives of matrix metalloproteinase inhibitors. Pharmacol Ther 2020; 207: 107465

    Article  CAS  Google Scholar 

  24. Pietrzak J, Mirowski M, Świechowski R, Wodziński D, Wosiak A, Michalska K, Balcerczak E. Importance of altered gene expression of metalloproteinases 2, 9, and 16 in acute myeloid leukemia: preliminary study. J Oncol 2021; 2021: 6697975

    Article  Google Scholar 

  25. Azevedo PL, Oliveira NCA, Corrêa S, Castelo-Branco MTL, Abdelhay E, Binato R. Canonical WNT signaling pathway is altered in mesenchymal stromal cells from acute myeloid leukemia patients and is implicated in BMP4 down-regulation. Transl Oncol 2019; 12(4): 614–625

    Article  Google Scholar 

  26. Marini JC, Forlino A, Bächinger HP, Bishop NJ, Byers PH, Paepe A, Fassier F, Fratzl-Zelman N, Kozloff KM, Krakow D, Montpetit K, Semler O. Osteogenesis imperfecta. Nat Rev Dis Primers 2017; 3(1): 17052

    Article  Google Scholar 

  27. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196(4): 395–406

    Article  CAS  Google Scholar 

  28. Chen W, Yang Z. Identification of differentially expressed genes reveals BGN predicting overall survival and tumor immune infiltration of gastric cancer. Comput Math Methods Med 2021; 2021: 5494840

    Article  Google Scholar 

  29. Jia YY, Yu Y, Li HJ. POSTN promotes proliferation and epithelial-mesenchymal transition in renal cell carcinoma through ILK/AKT/mTOR pathway. J Cancer 2021; 12(14): 4183–4195

    Article  CAS  Google Scholar 

  30. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 2017; 18(1): 248–262

    Article  CAS  Google Scholar 

  31. Smith IA, Knezevic BR, Ammann JU, Rhodes DA, Aw D, Palmer DB, Mather IH, Trowsdale J. BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation. J Immunol 2010; 184(7): 3514–3525

    Article  CAS  Google Scholar 

  32. Jiang Z, Liu F. Butyrophilin-like 9 (BTNL9) suppresses invasion and correlates with favorable prognosis of uveal melanoma. Med Sci Monit 2019; 25: 3190–3198

    Article  CAS  Google Scholar 

  33. Mo Q, Xu K, Luo C, Zhang Q, Wang L, Ren G. BTNL9 is frequently downregulated and inhibits proliferation and metastasis via the P53/CDC25C and P53/GADD45 pathways in breast cancer. Biochem Biophys Res Commun 2021; 553: 17–24

    Article  CAS  Google Scholar 

  34. Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev 2017; 60: 24–31

    Article  CAS  Google Scholar 

  35. Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. Cancers (Basel) 2020; 12(7): E1765

    Article  Google Scholar 

  36. Gulubova M, Aleksandrova E, Vlaykova T. Promoter polymorphisms in TGFB1 and IL10 genes influence tumor dendritic cells infiltration, development and prognosis of colorectal cancer. J Gene Med 2018; 20(2–3): e3005

    Article  Google Scholar 

  37. Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022; 19(4): 237–253

    Article  CAS  Google Scholar 

  38. Sarter K, Leimgruber E, Gobet F, Agrawal V, Dunand-Sauthier I, Barras E, Mastelic-Gavillet B, Kamath A, Fontannaz P, Guéry L, Duraes FV, Lippens C, Ravn U, Santiago-Raber ML, Magistrelli G, Fischer N, Siegrist CA, Hugues S, Reith W. Btn2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes. J Exp Med 2016; 213(2): 177–187

    Article  CAS  Google Scholar 

  39. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3(2): 133–146

    Article  CAS  Google Scholar 

  40. Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022; 19(4): 237–253

    Article  CAS  Google Scholar 

  41. Crespo J, Wu K, Li W, Kryczek I, Maj T, Vatan L, Wei S, Opipari AW, Zou W. Human naive T cells express functional CXCL8 and promote tumorigenesis. J Immunol 2018; 201(2): 814–820

    Article  CAS  Google Scholar 

  42. Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs 2010; 11(12): 1450–1465

    CAS  Google Scholar 

  43. Lerga A, Richard C, Delgado MD, Cañelles M, Frade P, Cuadrado MA, León J. Apoptosis and mitotic arrest are two independent effects of the protein phosphatases inhibitor okadaic acid in K562 leukemia cells. Biochem Biophys Res Commun 1999; 260(1): 256–264

    Article  CAS  Google Scholar 

  44. Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res 2005; 11(5): 1884–1889

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Key Research and Development Program of China (No. 2019YFA0905900).

Author information

Authors and Affiliations

  1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Ran Li, Kai Xue & Junmin Li

Authors
  1. Ran Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junmin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kai Xue or Junmin Li.

Additional information

Compliance with ethics guidelines

Ran Li, Kai Xue, and Junmin Li declare no conflict of interest. The study involved animals that were maintained and treated in accordance with Chinese legal requirements. The experiments were approved by the Ethics Committee of Ruijin Hospital Clinical Research Center, Shanghai Jiao Tong University School of Medicine, and the rules were strictly followed during the experiments.

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, R., Xue, K. & Li, J. FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches. Front. Med. 16, 896–908 (2022). https://doi.org/10.1007/s11684-022-0944-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-022-0944-z

Keywords

Search

Navigation